

Cell-Based Models of Tumour Angiogenesis

Michael John Plank

Submitted in accordance with the requirements for the degree of
Doctor of Philosophy

The University of Leeds,
Department of Applied Mathematics.

July 2003

The candidate confirms that the work submitted is his own and that appropriate credit has been given where reference has been made to the work of others.

This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement.

Acknowledgements

I would like to express my sincerest thanks to my supervisor, Professor Brian Sleeman, for his unfailing guidance and support. His knowledge of and enthusiasm for the subject are an inspiration and an example to any aspiring researcher.

In addition, I would like to thank Dr Pam Jones for helping a mathematician to understand the relevant biological processes, for bringing pertinent biological literature to my attention and for her aversion to the word ‘equation’. Thanks also go to everyone else who has helped during my studies at the University of Leeds, including Dr Sandy Anderson, Professor Nick Hill and Edd Codling.

Financial support from EPSRC studentship 00801007 and from the European Research Training Network is gratefully acknowledged.

Abstract

It is now accepted that a tumour must induce the growth of new blood vessels, a process called angiogenesis, in order to grow beyond a diameter of approximately 2 mm. Knowledge of angiogenesis has increased massively over the last 30 years, enabling mathematical models of the process to be constructed and analysed. Initially, modelling was done at the continuum (i.e. cell density) level but, more recently, the appreciation that angiogenesis is an inherently discrete process has led to increasing research using individual cell-based models.

In this thesis, tumour angiogenesis is modelled at the individual cell level, using techniques based on the theory of reinforced random walks, and cell-based simulations are carried out. The purpose of this work is to develop the modelling techniques, to improve understanding of angiogenesis and to highlight potential strategies for therapeutic intervention.

Chapters 1 and 2 contain an introduction to the relevant biological and mathematical literature respectively. In chapter 3, the theory of reinforced random walks is introduced. A result regarding the large time behaviour of one of the key governing equations is proved and a generalisation of the basic random walk model is presented, allowing a wider range of biological scenarios to be modelled.

In chapter 4, the basic model for cell movement is developed in close conjunction with experimental data. Chemokinesis, chemotaxis, haptotaxis are included and their relative contributions to cell movement discussed. In chapter 5, a model of tumour angiogenesis is formulated and used to simulate the growth of capillary networks. The model is also used to assess the potential of anti-angiogenic strategies. Chapter 6 develops a new model that includes the role of the angiopoietins, a recently discovered family of growth factors which have emerged as critical regulators of angiogenesis. In chapter 7, a model that frees the cells from geometric constraints (a non-lattice model) is developed, and critically compared to existing lattice-based models.

The material in chapters 4 and 5 has been accepted for publication [126, 127].

Contents

List of Abbreviations	xiii
Notation	xiv
1 Biological Introduction	1
1.1 Fundamentals of Tumour Biology	1
1.2 Biology of the Healthy Vasculature	5
1.3 Cell Proliferation and Migration	6
1.3.1 Proliferation	7
1.3.2 Migration	8
1.4 Tumour-Induced Angiogenesis	10
1.4.1 Historical Overview	12
1.4.2 Emergence from the Dormant Phase and the Angiogenic Switch	13
1.4.3 Initiation of Angiogenesis	14
1.4.4 Endothelial Cell Migration and Proliferation	15
1.4.5 The Vascular Phase	17

1.5	Pro- and Anti-Angiogenic Factors	18
1.5.1	Vascular Endothelial Growth Factor	20
1.5.2	Basic Fibroblast Growth Factor	21
1.5.3	Transforming Growth Factor Beta	21
1.5.4	Platelet-Derived Growth Factor	22
1.5.5	The Angiopoietins	22
1.5.6	Angiostatin	25
1.6	Invasion and Metastasis	26
1.7	Summary	27
2	Mathematical Introduction	29
2.1	Enzyme Kinetics	30
2.1.1	Notation and the Law of Mass Action	30
2.1.2	The Basic Enzymatic Reaction	31
2.1.3	Michaelis–Menten Theory	32
2.2	Population Growth Laws	35
2.3	Chemotaxis	36
2.3.1	Mathematical Description of Chemotaxis	37
2.3.2	Models of Chemotactic Behaviour	41
2.4	Solid Tumour Growth	46
2.5	Angiogenesis	52

2.5.1	Continuous Models	53
2.5.2	Discrete Models	65
2.6	Invasion and Metastasis	68
2.7	Summary	71
3	Reinforced Random Walks	73
3.1	The Reinforced Random Walk Master Equation	74
3.2	The Continuum Limit	77
3.2.1	Local Model	77
3.2.2	Barrier Model	78
3.2.3	Barrier Model with Normalisation	79
3.3	Steady State Solution of the Time-Independent Continuum Limit Equation	82
3.4	The Reinforced Random Walk with Variable Mean Waiting Time . .	85
3.4.1	Variable Lambda	86
3.4.2	Combination of Normalised and Unnormalised Barrier Models	87
3.5	Aggregation and Collapse in Discrete Time and Space	88
3.6	The Method of Simulation	92
3.7	Summary	94
4	A Model of an Experiment on Endothelial Cell Migration	96
4.1	The Experiment	96

4.2	The Mathematical Model	97
4.2.1	The Endothelial Cell Dynamics	99
4.2.2	The Substrate Dynamics	101
4.2.3	Non-Dimensionalisation	102
4.3	The Method of Simulation	104
4.4	Parameter Values	106
4.5	Results	107
4.6	Discussion	119
4.7	Summary	120
5	A Model of Tumour Angiogenesis and Anti-Angiogenic Strategies	122
5.1	The Mathematical Model	123
5.1.1	The Substrate Dynamics	124
5.1.2	The Endothelial Cell Dynamics	129
5.1.3	Initial, Boundary and Transmission Conditions	131
5.1.4	Non-Dimensionalisation	134
5.2	The Method of Simulation	138
5.3	Parameter Values	142
5.4	Results	143
5.5	Discussion	155
5.6	Summary	159

6	A Model for the Role of the Angiopoietins in Angiogenesis	160
6.1	The Mathematical Model	161
6.1.1	Model Assumptions	161
6.1.2	The Endothelial Cell Dynamics	163
6.1.3	The Substrate Dynamics	165
6.1.4	Initial and Boundary Conditions	166
6.1.5	Non-Dimensionalisation	167
6.2	The Method of Simulation	169
6.3	Parameter Values	169
6.4	Results	171
6.5	Discussion	181
6.6	Summary	184
7	Lattice and Non-Lattice Models	185
7.1	The Circular Random Walk Model	186
7.2	Non-Lattice Model of Angiogenesis	188
7.2.1	Turning Rate Statistics	188
7.2.2	Haptotaxis	190
7.2.3	Substrate Profiles	191
7.2.4	Non-Dimensionalisation	193
7.3	The Method of Simulation	194

7.4	Parameter Values	195
7.5	Lattice-Based Models	195
7.5.1	Lattice Model I	197
7.5.2	Lattice Model II	198
7.6	Results	199
7.7	Discussion	209
7.8	Three-Dimensional Non-Lattice Model	214
7.9	Results and Discussion	221
7.10	Summary	223
Appendices		224
A Numerical Solution of Reaction–Diffusion Equations		224
B Upper and Lower Solutions to a Reaction–Diffusion Equation		226
Bibliography		229

List of Tables

1.1	Angiogenic activators and inhibitors.	19
4.1	Parameter values used in the simulations.	105
5.1	Constants resulting from the non-dimensionalisation of the model. .	137
5.2	Parameter values used in the simulations.	137
6.1	Constants resulting from the non-dimensionalisation of the model. .	168
6.2	Parameter values used in the numerical solutions.	169
7.1	Parameter values for the non-lattice model.	196
7.2	Parameter values for the lattice-based models.	196

List of Figures

1.1	A schematic diagram of a benign and a malignant tumour.	2
1.2	A schematic diagram of a vascularised tumour.	4
1.3	A schematic diagram of the endothelium.	5
1.4	The process of mitosis.	7
1.5	The cell cycle.	8
1.6	The response of a cell to a chemical gradient.	9
1.7	The chemotactic aggregation of bacteria at a food source.	9
1.8	The key events of angiogenesis.	11
1.9	An experimental model for angiogenesis in the cornea.	12
1.10	Experimental capillary networks formed by angiogenesis.	17
1.11	Regulation of EC by the angiopoietins and VEGF.	24
2.1	Travelling wave solutions of a chemotaxis model.	42
2.2	Similarity solutions of a chemotaxis model.	43
2.3	Blowup and collapse solutions of a chemotaxis model.	45
2.4	Solutions of a model of solid tumour growth.	49

2.5	Solutions of a model of solid tumour growth.	51
2.6	Initial conditions for EC, TAF and fibronectin.	58
2.7	The solution of a model of angiogenesis without angiostatin.	62
2.8	The solution of a model of angiogenesis with angiostatin.	63
2.9	Simulations of a discrete model of angiogenesis.	67
3.1	The generic simulation algorithm.	93
4.1	A diagram of the experiment.	97
4.2	The 2D model.	98
4.3	A graph of average radial invasion against VEGF concentration. . .	108
4.4	EC migration in the xy -plane.	109
4.5	EC migration in the xz -plane.	110
4.6	Evolution of the collagen profile.	111
4.7	Experimental results.	112
4.8	A simulation with reduced VEGF.	112
4.9	A simulation with no VEGF.	113
4.10	A simulation with the lower solution for VEGF.	114
4.11	A simulation with the time-dependent upper solution for VEGF. . .	115
4.12	The time-dependent upper solution for VEGF.	116
4.13	A 2D simulation with a point source of VEGF.	118
4.14	A 2D simulation with an increased point source of VEGF.	120

4.15	A 2D simulation with a point source of VEGF and no collagen. . . .	121
5.1	A diagram of the model geometry.	124
5.2	A schematic diagram of growing capillaries.	134
5.3	Positions of the EC in the capillary.	138
5.4	Evolution of the VEGF profile in the capillary.	139
5.5	Evolution of the protease profile in the capillary.	140
5.6	Evolution of the fibronectin profile in the capillary.	141
5.7	Trails formed by the EC in the ECM.	143
5.8	Evolution of the substrate profiles in the ECM.	144
5.9	Evolution of the fibronectin profile in the ECM.	145
5.10	Trails formed in the absence of EC proliferation.	147
5.11	Trails formed with reduced VEGF.	147
5.12	Trails formed with increased VEGF.	149
5.13	Trails formed with increased VEGF.	150
5.14	Evolution of the VEGF profile.	150
5.15	Evolution of the protease profile with increased VEGF.	151
5.16	Trails formed with very high VEGF.	151
5.17	Trails formed with angiostatin.	153
5.18	Evolution of the VEGF profile with angiostatin.	154
5.19	Evolution of the fibronectin profile with angiostatin.	154

5.20	Evolution of the angiostatin profile.	155
5.21	Evolution of the protease profiles with angiostatin.	156
5.22	Trails formed when angiostatin is introduced at $t = 4$ h.	157
5.23	Trails formed when the source of VEGF is removed.	158
5.24	Evolution of the VEGF profile when the source of VEGF is removed.	158
6.1	Graphs of the vascularisation time against the parameters α and β	171
6.2	Time course for immature EC density.	172
6.3	Time course for mature EC density.	173
6.4	Time course for Ang-1 concentration.	175
6.5	Time course for Ang-2 concentration.	176
6.6	The steady state VEGF concentration.	176
6.7	Time course for immature EC density with no Ang-2.	177
6.8	Time course for mature EC density with no Ang-2.	177
6.9	Time course for immature EC density with no Ang-1 expression.	178
6.10	Time course for mature EC density with no Ang-1 expression.	178
6.11	Time course for immature EC density with increased Ang-2 expression.	179
6.12	Time course for mature EC density with increased Ang-2 expression.	179
6.13	Time course for immature EC density with increased Ang-1 expression.	182
6.14	Time course for mature EC density with increased Ang-1 expression.	182
6.15	Time course for immature EC density with no VEGF.	183

6.16	Time course for immature EC density with a modified initial condition.	183
7.1	Trails formed in the non-lattice model with a point source of VEGF.	199
7.2	Trails formed in the non-lattice model with a line source of VEGF.	199
7.3	Trails formed in the non-lattice model with altered turning rate variance.	200
7.4	Trails formed in the non-lattice model with altered turning coefficient.	201
7.5	Trails formed in the non-lattice model with altered branching rate.	202
7.6	Trails formed in the non-lattice model with desensitisation.	204
7.7	Trails formed in the non-lattice model with haptotaxis.	205
7.8	A graph of the network extension rate against the haptotactic coefficient.	206
7.9	Trails formed in the lattice-based models.	210
7.10	Trails formed in the lattice-based models with increased chemotaxis.	210
7.11	Trails formed in the lattice-based models with desensitisation.	211
7.12	Trails formed in the lattice-based models with haptotaxis.	211
7.13	Trails formed in the 3D non-lattice model.	219
7.14	Trails formed in the 3D non-lattice model with desensitisation.	220
7.15	Trails formed in the 3D non-lattice model with two tumours.	220
7.16	A graph of the number of anastomoses against EC radius.	221

List of Abbreviations

AMP	Adenosine monophosphate
Ang	Angiopoietin
bFGF	Basic fibroblast growth factor
Da	Dalton (unit of molecular weight)
DNA	Deoxyribonucleic acid
EC	Endothelial cell(s)
ECM	Extracellular matrix
M	Molar (1 mol/l)
MMP	Matrix metalloprotease
mRNA	Messenger ribonucleic acid
ODE	Ordinary differential equation
PA	Plasminogen activator
PAI	Plasminogen activator inhibitor
PDE	Partial differential equation
PDGF	Platelet-derived growth factor
TAF	Tumour angiogenesis factor
TGF	Transforming growth factor
TIMP	Tissue inhibitor of metalloproteases
VEGF	Vascular endothelial growth factor

Notation

$\mathbb{Z}$, $\mathbb{R}$ and $\mathbb{C}$ respectively denote the sets of integer, real and complex numbers. For $N \in \mathbb{Z}$, $\mathbb{R}^N$ denotes the N -dimensional set $\{(x_1, \dots, x_N) : x_i \in \mathbb{R}, i = 1, \dots, N\}$.

For $a, b \in \mathbb{R}$, $[a, b] \subseteq \mathbb{R}$ is used to denote the interval of the real line, $\{x \in \mathbb{R} : a \leq x < b\}$. The only possible ambiguity is (a, b) , which is also used to denote a member of $\mathbb{R}^2$, but the intended meaning will always be made clear from the context.

For two sets, A and B , $A \times B$ denotes the set of pairs of elements of A and B , $\{(a, b) : a \in A, b \in B\}$. For $m \in \mathbb{R}$, $A^{\geq m}$ denotes the set $\{a \in A : a \geq m\}$. $f : A \rightarrow B$ denotes a function with domain A and range B .

For $\Omega \subset \mathbb{R}^N$, the boundary of Ω is denoted by $\partial\Omega$, the set of $x \in \mathbb{R}^N$ satisfying: (i) $\exists x_1, x_2, \dots \in \Omega$ such that $\lim_{n \rightarrow \infty} x_n = x$; (ii) $\forall \epsilon > 0, \exists y \notin \Omega$ such that $|x - y| < \epsilon$.

For $n \in \mathbb{Z}$ and $A \subseteq \mathbb{C}$, $C^n(A)$ is used to denote the set of n times continuously differentiable functions, $f : A \rightarrow \mathbb{C}$. Unless stated otherwise, the symbol $'$ denotes differentiation of a function $f : A \rightarrow \mathbb{C}$ with respect to its argument.

The gradient operator is denoted by $\nabla = \left(\frac{\partial}{\partial x}, \frac{\partial}{\partial y}, \frac{\partial}{\partial z} \right)$; the divergence of a vector field, $F : \mathbb{R}^3 \rightarrow \mathbb{R}^3$, is denoted by $\nabla \cdot F$; the Laplacian operator is denoted by $\nabla^2 \equiv \nabla \cdot \nabla$.

For $n \in \mathbb{Z}$, $J_n : \mathbb{C} \rightarrow \mathbb{C}$ and $I_n : \mathbb{C} \rightarrow \mathbb{C}$ respectively represent the Bessel function and the modified Bessel function of the first kind and n^{th} order.

For $N \in \mathbb{Z}^{>0}$, $I^{[N]}$ denotes the $N \times N$ identity matrix, defined by $I_{ij}^{[N]} = \begin{cases} 1, & i = j \\ 0, & i \neq j \end{cases}$ for $i, j = 1, \dots, N$.

$\delta : \mathbb{R} \rightarrow \mathbb{R}$ denotes the Dirac delta function, defined by $\delta(x) = 0$ for $x \neq 0$ and $\int_{-\infty}^{\infty} \delta(x) f(x) dx = f(0)$ for any function $f \in C^0(\mathbb{R})$. $H : \mathbb{R} \rightarrow \mathbb{R}$ denotes the Heaviside step function, defined by $H' = \delta$ and $H(x) = 1$ for $x > 0$.

$P(\cdot) \in [0, 1]$ is the standard probability measure function and $P(A|B)$ denotes the conditional probability of A occurring given that B has occurred. $E(X)$ and $\text{Var}(X)$ respectively denote the expected value and the variance of the random variable, X .